Waiv, formerly the diagnostics division of AI biotech Owkin, developed AI-enabled testing technologies that found use in clinical settings and in cancer drug research. Spinning out as an independent company enables Waiv to pursue its own growth strategy, co-founder and CEO Meriem Sefta said.
The post Startup Waiv Spins Out of Owkin With $33M to Bring AI Precision to Cancer Decisions appeared first on MedCity News.
